0XOD logo

UroGen Pharma LSE:0XOD Stock Report

Last Price

US$10.46

Market Cap

US$452.0m

7D

-8.3%

1Y

-27.9%

Updated

24 Dec, 2024

Data

Company Financials +

0XOD Stock Overview

A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. More details

0XOD fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

UroGen Pharma Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for UroGen Pharma
Historical stock prices
Current Share PriceUS$10.46
52 Week HighUS$20.47
52 Week LowUS$10.31
Beta1.07
1 Month Change-10.77%
3 Month Change-18.83%
1 Year Change-27.88%
3 Year Change9.96%
5 Year Changen/a
Change since IPO-75.10%

Recent News & Updates

Recent updates

Shareholder Returns

0XODGB BiotechsGB Market
7D-8.3%-5.0%-1.9%
1Y-27.9%-24.4%2.6%

Return vs Industry: 0XOD underperformed the UK Biotechs industry which returned -24.4% over the past year.

Return vs Market: 0XOD underperformed the UK Market which returned 2.6% over the past year.

Price Volatility

Is 0XOD's price volatile compared to industry and market?
0XOD volatility
0XOD Average Weekly Movement7.3%
Biotechs Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0XOD's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0XOD's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2004217Liz Barrettwww.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).

UroGen Pharma Ltd. Fundamentals Summary

How do UroGen Pharma's earnings and revenue compare to its market cap?
0XOD fundamental statistics
Market capUS$451.96m
Earnings (TTM)-US$115.38m
Revenue (TTM)US$89.36m

5.1x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0XOD income statement (TTM)
RevenueUS$89.36m
Cost of RevenueUS$8.70m
Gross ProfitUS$80.67m
Other ExpensesUS$196.05m
Earnings-US$115.38m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.73
Gross Margin90.27%
Net Profit Margin-129.11%
Debt/Equity Ratio477.0%

How did 0XOD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 20:57
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UroGen Pharma Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jonathan AschoffB. Riley Wealth
Jason KolbertD. Boral Capital LLC.